Wed, Oct 16, 2024
Volume 16, Issue 6 (Special issue (Nov-Dec) 2022)
mljgoums 2022, 16(6): 20-25 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yaseri M, Mortazavi Khatibani S S, Naeimi A, Fayazi H S. Association between C-Reactive Protein Test Result and Clinical Characteristics in Patients with COVID-19. mljgoums 2022; 16 (6) :20-25
URL: http://mlj.goums.ac.ir/article-1-1560-en.html
URL: http://mlj.goums.ac.ir/article-1-1560-en.html
1- Department of Internal Medicine, School of Medicine, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran
2- Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3- Department of Internal Medicine, School of Medicine, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran ,fayazihaniyehsadat@gmail.com
2- Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3- Department of Internal Medicine, School of Medicine, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran ,
Abstract: (1653 Views)
Background and objectives: In coronavirus disease 2019 (COVID-19), elevated serum levels of C-reactive protein (CRP), a marker of systemic inflammation, are commonly observed. We aimed to investigate the associations between CRP test results and clinical characteristics in patients with COVID-19.
Method: In this cross-sectional study, data from 399 patients with COVID-19 were collected through a census method. The patients were divided into a CRP-positive group (n=335) and a CRP-negative group (n=64). Demographical data, laboratory findings, clinical characteristics, and history of some underlying diseases were compared between the two groups. All analyses were carried out in SPSS (version 21).
Results: The frequency of hypertension was 40.1% among the study population, 42.4 % among CRP-positive patients, and 28.1% among CRP-negative patients. Diabetes and heart disease were the most common comorbidities among the patients. Dyspnea (60.4%), fever (52.7%), fatigue (45.4%), and dry cough (40.1%) were the most commonly observed symptoms. The mean duration of hospitalization was 8.14±6.18 days, and the mean duration of intensive care unit stay was 9.09±9.41 days. Moreover, CRP positivity was significantly associated with hypertension, immunosuppressive therapy, and higher duration of hospitalization (p<0.05).
Conclusion: Pre-existing hypertension, diabetes, and heart disease with the coincidence of some clinical symptoms are associated with higher levels of CRP in COVID-19 patients, which results in longer hospitalization.
Method: In this cross-sectional study, data from 399 patients with COVID-19 were collected through a census method. The patients were divided into a CRP-positive group (n=335) and a CRP-negative group (n=64). Demographical data, laboratory findings, clinical characteristics, and history of some underlying diseases were compared between the two groups. All analyses were carried out in SPSS (version 21).
Results: The frequency of hypertension was 40.1% among the study population, 42.4 % among CRP-positive patients, and 28.1% among CRP-negative patients. Diabetes and heart disease were the most common comorbidities among the patients. Dyspnea (60.4%), fever (52.7%), fatigue (45.4%), and dry cough (40.1%) were the most commonly observed symptoms. The mean duration of hospitalization was 8.14±6.18 days, and the mean duration of intensive care unit stay was 9.09±9.41 days. Moreover, CRP positivity was significantly associated with hypertension, immunosuppressive therapy, and higher duration of hospitalization (p<0.05).
Conclusion: Pre-existing hypertension, diabetes, and heart disease with the coincidence of some clinical symptoms are associated with higher levels of CRP in COVID-19 patients, which results in longer hospitalization.
Research Article: Research Article |
Subject:
Laboratory Sciences
Received: 2022/08/9 | Accepted: 2022/12/14 | Published: 2022/11/25 | ePublished: 2022/11/25
Received: 2022/08/9 | Accepted: 2022/12/14 | Published: 2022/11/25 | ePublished: 2022/11/25
References
1. Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020/06/10. 2020; 56(2): 106054. [View at Publisher] [DOI:10.1016/j.ijantimicag.2020.106054] [PubMed] [Google Scholar]
2. Luan Y-Y, Yin C-H, Yao Y-M. Update Advances on C-Reactive Protein in COVID-19 and Other Viral Infections. Front Immunol. 2021;12:720363. [View at Publisher] [DOI:10.3389/fimmu.2021.720363] [PubMed] [Google Scholar]
3. Yaghubi T, Shakoori V, Nasiri S, Keivan M, Tavakol C, Ahanjide S, et al. Clinical characteristics and outcomes of COVID-19 patients with a history of cardiovascular disease. J Curr Biomed Reports. 2022;3(1): 1-7. [View at Publisher] [DOI:10.52547/jcbior.3.1.36] [Google Scholar]
4. Zeinali T, Faraji N, Joukar F, Khan Mirzaei M, Kafshdar Jalali H, Shenagari M, et al. Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm. Microb Pathog. 2022; 105704. [View at Publisher] [DOI:10.1016/j.micpath.2022.105704] [PubMed] [Google Scholar]
5. Halaji M, Heiat M, Faraji N, Ranjbar R. Epidemiology of COVID-19: An updated review. J Res Med Sci. 2021; 26: 82. [PubMed] [Google Scholar]
6. Eastin C, Eastin T. Clinical Characteristics of Coronavirus Disease 2019 in China: Guan W, Ni Z, Hu Y, et al. N Engl J Med. 2020 Feb 28 [Online ahead of print] DOI: 10.1056/NEJMoa2002032. J Emerg Med [Internet]. 2020/06/03. 2020 Apr;58(4):711-2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266766/ [DOI:10.1016/j.jemermed.2020.04.004]
7. Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A . COPE Study Collaborators. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021
17;50(2):420-429 [View at Publisher] [DOI:10.1093/ije/dyab012] [PubMed] [Google Scholar]
8. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020 Jun;80(6):656-65. [View at Publisher] [DOI:10.1016/j.jinf.2020.03.041] [PubMed] [Google Scholar]
9. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020 Jun;80(6):656-665. [View at Publisher] [DOI:10.1016/j.neurad.2020.04.003] [PubMed] [Google Scholar]
10. Rainer TH, Chan CPY, Leung MF, Leung W, Ip M, Lee N, et al. Diagnostic utility of CRP to neopterin ratio in patients with acute respiratory tract infections. J Infect. 2009;58(2):123-30. [View at Publisher] [DOI:10.1016/j.jinf.2008.11.007] [Google Scholar]
11. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000; 192(9):1353-64. [DOI:10.1084/jem.192.9.1353] [PubMed] [Google Scholar]
12. Nagasawa S. C-Reactive Protein: New Research. Nova Science Publishers, Incorporated; 2009.
13. Coster D, Wasserman A, Fisher E, Rogowski O, Zeltser D, Shapira I, et al . Using the kinetics of C-reactive protein response to improve the differential diagnosis between acute bacterial and viral infections. Infection. 2020 ;48(2):241-248. [View at Publisher] [DOI:10.1007/s15010-019-01383-6] [PubMed] [Google Scholar]
14. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020 ;127:104370. [View at Publisher] [DOI:10.1016/j.jcv.2020.104370] [PubMed] [Google Scholar]
15. Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta. 2020 ;509:91-94. [View at Publisher] [DOI:10.1016/j.cca.2020.06.013] [PubMed] [Google Scholar]
16. Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020 ;92(11):2409-2411. [View at Publisher] [DOI:10.1002/jmv.26097] [PubMed] [Google Scholar]
17. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al . C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 14;42(23):2270-2279. [DOI:10.1093/eurheartj/ehaa1103] [PubMed] [Google Scholar]
18. Basso C, Leone O, Rizzo S, De Gaspari M, van der Wal AC, Aubry MC, et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020 14;41(39):3827-3835. [View at Publisher] [DOI:10.1093/eurheartj/ehaa664] [PubMed] [Google Scholar]
19. Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020 Jun;41(22):2070-9. [View at Publisher] [DOI:10.1093/eurheartj/ehaa408] [PubMed] [Google Scholar]
20. Pecly IMD, Azevedo RB, Muxfeldt ES, Botelho BG, Albuquerque GG, Diniz PHP, et al. COVID-19 and chronic kidney disease: a comprehensive review. J Bras Nefrol. 2021;43(3):383-399. [View at Publisher] [DOI:10.1590/2175-8239-jbn-2020-0203] [PubMed] [Google Scholar]
21. Ajaimy M, Melamed ML. COVID-19 in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2020; 15(8): 1087 LP - 1089. [View at Publisher] [DOI:10.2215/CJN.09730620]
22. Wang Y, Zhang F, Byrd JB, Yu H, Ye X, He Y. Differential COVID-19 Symptoms Given Pandemic Locations, Time, and Comorbidities During the Early Pandemic. Front Med (Lausanne). 2022; 9: 770031. [View at Publisher] [DOI:10.3389/fmed.2022.770031] [PubMed] [Google Scholar]
23. Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020; 61(3): E304-12.
24. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020; 395(10223): 497-506. [DOI:10.1016/S0140-6736(20)30183-5]
25. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis. 2020; 20(5): 559-64. [View at Publisher] [DOI:10.1016/S1473-3099(20)30176-6] [PubMed] [Google Scholar]
26. Lentner J, Adams T, Knutson V, Zeien S, Abbas H, Moosavi R, et al. C-reactive protein levels associated with COVID-19 outcomes in the United States. J Osteopath Med. 2021;121(12):869-73. [View at Publisher] [DOI:10.1515/jom-2021-0103]
27. Mardani R, namavar M, ghorbi E, Shoja Z, Zali F, Kaghazian H, et al. Association between serum inflammatory parameters and the disease severity in COVID-19 patients. J Clin Lab Anal [Internet]. 2022; 36(1): e24162. [View at Publisher] [DOI:10.1002/jcla.24162] [Google Scholar]
28. Kaya T, Nalbant A, Karata G. The prognostic significance of erythrocyte seacdimentation rate in COVID-19. 2021; 67(9): 1305-10. [View at Publisher] [DOI:10.1590/1806-9282.20210618] [PubMed]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.